{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T01:35:00Z","timestamp":1787016900466,"version":"build-2736575974"},"reference-count":36,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2008,10,1]],"date-time":"2008-10-01T00:00:00Z","timestamp":1222819200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2008,10,1]],"date-time":"2008-10-01T00:00:00Z","timestamp":1222819200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2008,10]]},"DOI":"10.1136\/ard.2007.077891","type":"journal-article","created":{"date-parts":[[2008,1,15]],"date-time":"2008-01-15T22:32:35Z","timestamp":1200436355000},"page":"1437-1443","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":69,"title":["Lack of efficacy of etanercept in Sj\u00f6gren syndrome correlates with failed suppression of tumour necrosis factor \u03b1 and systemic immune activation"],"prefix":"10.1016","volume":"67","author":[{"given":"N M","family":"Moutsopoulos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G E","family":"Katsifis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N","family":"Angelov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R A","family":"Leakan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V","family":"Sankar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Pillemer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S M","family":"Wahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1136\/ard.2007.077891_bib1","first-page":"191","article-title":"Sj\u00f6gren\u2019s syndrome: current concepts.","volume":"47","author":"Manoussakis","year":"2001","journal-title":"Adv Intern Med"},{"key":"10.1136\/ard.2007.077891_bib2","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1111\/j.1601-0825.2006.01292.x","article-title":"Sj\u00f6gren\u2019s syndrome: why autoimmune epithelitis?","volume":"12","author":"Mitsias","year":"2006","journal-title":"Oral Dis"},{"key":"10.1136\/ard.2007.077891_bib3","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1111\/j.0300-9475.2004.01432.x","article-title":"Circulating cytokines in primary Sj\u00f6gren\u2019s syndrome determined by a multiplex cytokine array system.","volume":"59","author":"Szodoray","year":"2004","journal-title":"Scand J Immunol"},{"key":"10.1136\/ard.2007.077891_bib4","first-page":"131","article-title":"Tumor necrosis factor-alpha and receptors for it in labial salivary glands in Sj\u00f6gren\u2019s syndrome.","volume":"19","author":"Koski","year":"2001","journal-title":"Clin Exp Rheumatol"},{"key":"10.1136\/ard.2007.077891_bib5","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/ncprheum0165","article-title":"The management of Sj\u00f6gren\u2019s syndrome.","volume":"2","author":"Mavragani","year":"2006","journal-title":"Nat Clin Pract Rheumatol"},{"key":"10.1136\/ard.2007.077891_bib6","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1517\/13543784.12.7.1087","article-title":"The therapeutic potential of TNF-alpha blockade in rheumatoid arthritis.","volume":"12","author":"Paleolog","year":"2003","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1136\/ard.2007.077891_bib7","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1136\/ard.2004.020719","article-title":"TNF\u03b1 therapy in psoriatic arthritis and psoriasis.","volume":"63","author":"Mease","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2007.077891_bib8","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.2174\/156802606778194217","article-title":"Anti-TNF-alpha antibody therapies in autoimmune diseases.","volume":"6","author":"Chatzantoni","year":"2006","journal-title":"Curr Top Med Chem"},{"key":"10.1136\/ard.2007.077891_bib9","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1002\/art.20146","article-title":"Inefficacy of infliximab in primary Sj\u00f6gren\u2019s syndrome: results of the randomized, controlled Trial of Remicade in Primary Sj\u00f6gren\u2019s Syndrome (TRIPSS).","volume":"50","author":"Mariette","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2007.077891_bib10","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1002\/art.20299","article-title":"Etanercept in Sj\u00f6gren\u2019s syndrome: a twelve-week randomized, double-blind, placebo-controlled pilot clinical trial.","volume":"50","author":"Sankar","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2007.077891_bib11","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1056\/NEJM200103223441207","article-title":"Cytokine pathways and joint inflammation in rheumatoid arthritis.","volume":"344","author":"Choy","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1136\/ard.2007.077891_bib12","doi-asserted-by":"crossref","first-page":"3995","DOI":"10.1002\/art.23062","article-title":"Exagerration of Interferon-alpha pathway and BAFF production in patients with Sj\u00f6gren\u2019s syndrome after anti-TNF treatment.","volume":"56","author":"Mavragani","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2007.077891_bib13","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1136\/ard.61.6.554","article-title":"Classification criteria for Sj\u00f6gren\u2019s syndrome: a revised version of the European criteria proposed by the American-European Consensus Group.","volume":"61","author":"Vitali","year":"2002","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2007.077891_bib14","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1136\/jcp.21.5.656","article-title":"Labial salivary gland biopsy in Sj\u00f6gren\u2019s disease.","volume":"21","author":"Chisholm","year":"1968","journal-title":"J Clin Pathol"},{"key":"10.1136\/ard.2007.077891_bib15","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1002\/art.1780370615","article-title":"Association of patterns of labial salivary gland inflammation with keratoconjunctivitis sicca. Analysis of 618 patients with suspected Sj\u00f6gren\u2019s syndrome.","volume":"37","author":"Daniels","year":"1994","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2007.077891_bib16","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1136\/ard.2005.038406","article-title":"Immunological consequences of thalidomide treatment in Sj\u00f6gren\u2019s syndrome.","volume":"65","author":"Moutsopoulos","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2007.077891_bib17","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1002\/art.21006","article-title":"Gene expression profiling of minor salivary glands clearly distinguishes primary Sj\u00f6gren\u2019s syndrome patients from healthy control subjects.","volume":"52","author":"Hjelmervik","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2007.077891_bib18","doi-asserted-by":"crossref","first-page":"2770","DOI":"10.1073\/pnas.0510837103","article-title":"Activation of IFN pathways and plasmacytoid dendritic cell recruitment in target organs of primary Sj\u00f6gren\u2019s syndrome.","volume":"103","author":"Gottenberg","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1136\/ard.2007.077891_bib19","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1096\/fj.06-6084fje","article-title":"IL-10-induced TNF-alpha mRNA destabilization is mediated via IL-10 suppression of p38 MAP kinase activation and inhibition of HuR expression.","volume":"20","author":"Rajasingh","year":"2006","journal-title":"FASEB J"},{"key":"10.1136\/ard.2007.077891_bib20","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/S0002-9149(02)02494-3","article-title":"Effect of interleukin-10 on the production of tumor necrosis factor-alpha by peripheral blood mononuclear cells from patients with chronic heart failure.","volume":"90","author":"Bolger","year":"2002","journal-title":"Am J Cardiol"},{"key":"10.1136\/ard.2007.077891_bib21","doi-asserted-by":"crossref","first-page":"6316","DOI":"10.1074\/jbc.M508608200","article-title":"Divergent mechanisms utilized by SOCS3 to mediate interleukin-10 inhibition of tumor necrosis factor alpha and nitric oxide production by macrophages.","volume":"281","author":"Qasimi","year":"2006","journal-title":"J Biol Chem"},{"key":"10.1136\/ard.2007.077891_bib22","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1093\/rheumatology\/34.4.326","article-title":"Cytokine mRNA expression in the labial salivary gland tissues from patients with primary Sj\u00f6gren\u2019s syndrome.","volume":"34","author":"Boumba","year":"1995","journal-title":"Br J Rheumatol"},{"key":"10.1136\/ard.2007.077891_bib23","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1002\/art.10315","volume":"46","author":"Azuma","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2007.077891_bib24","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1172\/JCI118879","article-title":"Inhibition of submandibular and lacrimal gland infiltration in nonobese diabetic mice by transgenic expression of soluble TNF-receptor p55.","volume":"98","author":"Hunger","year":"1996","journal-title":"J Clin Invest"},{"key":"10.1136\/ard.2007.077891_bib25","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1046\/j.1365-3083.1999.00533.x","article-title":"Increased frequency of cells secreting interleukin-6 and interleukin-10 in peripheral blood of patients with primary Sj\u00f6gren\u2019s syndrome.","volume":"49","author":"Halse","year":"1999","journal-title":"Scand J Immunol"},{"key":"10.1136\/ard.2007.077891_bib26","first-page":"411","article-title":"Circulating levels of Th1\/Th2 cytokines in patients with primary Sj\u00f6gren\u2019s syndrome: correlation with clinical and immunological features.","volume":"19","author":"Garcic-Carrasco","year":"2001","journal-title":"Clin Exp Rheumatol"},{"key":"10.1136\/ard.2007.077891_bib27","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.immuni.2006.06.002","article-title":"Th17: an effector CD4 T cell lineage with regulatory T cell ties.","volume":"24","author":"Weaver","year":"2006","journal-title":"Immunity"},{"key":"10.1136\/ard.2007.077891_bib28","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.coi.2006.03.017","article-title":"Expanding the effector CD4 T-cell repertoire: the Th17 lineage.","volume":"18","author":"Harrington","year":"2006","journal-title":"Curr Opin Immunol"},{"key":"10.1136\/ard.2007.077891_bib29","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.coi.2006.11.008","article-title":"Transforming growth factor-beta: innately bipolar.","volume":"19","author":"Wahl","year":"2007","journal-title":"Curr Opin Immunol"},{"key":"10.1136\/ard.2007.077891_bib30","first-page":"252","article-title":"T lymphocytes in Sj\u0151gren\u2019s syndrome: contributors to and regulators of pathophysiology.","volume":"32","author":"Katsifis","year":"2007","journal-title":"Clin Rev Immunol"},{"key":"10.1136\/ard.2007.077891_bib31","first-page":"3","article-title":"IL-17 and TGF-beta: new allies in a gutsy battle.","volume":"14","author":"Vazquez","year":"2007","journal-title":"Mucosal Immunol Update"},{"key":"10.1136\/ard.2007.077891_bib32","first-page":"126","article-title":"The possible role of tumor necrosis factor (TNF) and its natural inhibitors, the soluble-TNF receptors, in autoimmune diseases.","volume":"28","author":"Aderka","year":"1992","journal-title":"Isr J Med Sci"},{"key":"10.1136\/ard.2007.077891_bib33","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0145-2126(02)00082-6","article-title":"Pilot study of recombinant human soluble tumor necrosis factor (TNF) receptor (p75) fusion protein (TNFR:Fc; Enbrel) in patients with refractory multiple myeloma: increase in plasma TNF alpha levels during treatment.","volume":"27","author":"Tsimberidou","year":"2003","journal-title":"Leuk Res"},{"key":"10.1136\/ard.2007.077891_bib34","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1093\/rheumatology\/kei090","article-title":"Systemic cytokine levels and the effects of etanercept in TNF receptor-associated periodic syndrome (TRAPS) involving a C33Y mutation in TNFRSF1A.","volume":"45","author":"Nowlan","year":"2006","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/ard.2007.077891_bib35","doi-asserted-by":"crossref","first-page":"6528","DOI":"10.1158\/1078-0432.CCR-04-0730","article-title":"A phase II study of etanercept (Enbrel), a tumor necrosis factor alpha inhibitor in patients with metastatic breast cancer.","volume":"10","author":"Madhusudan","year":"2004","journal-title":"Clin Cancer Res"},{"issue":"Suppl 28","key":"10.1136\/ard.2007.077891_bib36","first-page":"S34","article-title":"Immunological basis for the use of TNFalpha-blocking agents in ankylosing spondylitis and immunological changes during treatment.","volume":"20","author":"Zou","year":"2002","journal-title":"Clin Exp Rheumatol"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724427581?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724427581?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ard.2007.077891","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T00:17:03Z","timestamp":1736122623000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496724427581"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,10]]},"references-count":36,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2008,10]]}},"alternative-id":["S0003496724427581"],"URL":"https:\/\/doi.org\/10.1136\/ard.2007.077891","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2008,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lack of efficacy of etanercept in Sj\u00f6gren syndrome correlates with failed suppression of tumour necrosis factor \u03b1 and systemic immune activation","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ard.2007.077891","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2008 2008 Published by Elsevier Inc. Publishing Group and European League Against Rheumatism. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}